Loading...
OTCM
HOFBF
Market cap65mUSD
Nov 03, Last price  
0.17USD
Name

Hofseth Biocare ASA

Chart & Performance

D1W1MN
OTCM:HOFBF chart
P/E
—
P/S
2.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.05%
Rev. gr., 5y
30.59%
Revenues
257m
+32.09%
171,0001,183,00026,015,00062,936,00019,769,00055,137,00020,204,000118,476,00060,740,00067,778,00069,252,00087,616,000120,448,000194,874,000257,417,000
Net income
-123m
L+15.67%
-9,387,000-19,036,000-73,860,000-52,136,000-66,918,000-100,194,000-147,450,000-16,475,000-84,768,000-89,209,000-102,090,000-126,463,000-137,389,000-106,683,000-123,405,000
CFO
-10m
L
-12,445,000-19,470,000-48,006,000-83,652,000-62,257,0007,967,000-67,226,000-25,485,000-28,625,000-31,060,000-61,632,000-61,779,000-45,168,0002,761,000-9,780,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.
URL
https://hofsethbiocare.com
IPO date
Dec 02, 2011
Employees
56
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT